HC Wainwright Lowers Earnings Estimates for Nuvation Bio

Nuvation Bio Inc. (NYSE:NUVB) – Analysts at HC Wainwright dropped their FY2026 EPS estimates for Nuvation Bio in a report released on Thursday, November 5th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.34) per share for the year, down from their previous estimate of ($0.33). HC Wainwright has a “Buy” rating and a $21.00 price target on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q2 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.13) EPS.

Nuvation Bio (NYSE:NUVB) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.12). The business had revenue of $44.95 million during the quarter, compared to the consensus estimate of $34.39 million. Nuvation Bio had a negative net margin of 67.38% and a negative return on equity of 45.69%.

A number of other research analysts also recently weighed in on NUVB. Cantor Fitzgerald assumed coverage on shares of Nuvation Bio in a research report on Friday, August 21st. They set an “overweight” rating for the company. Citigroup reiterated a “market outperform” rating on shares of Nuvation Bio in a research report on Monday, October 19th. B. Riley Financial reiterated a “buy” rating on shares of Nuvation Bio in a research note on Friday, August 7th. Wedbush reissued an “outperform” rating and issued a $11.00 price target on shares of Nuvation Bio in a research report on Wednesday, September 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvation Bio in a research report on Thursday, October 15th. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Nuvation Bio has a consensus rating of “Moderate Buy” and an average target price of $12.89.

Nuvation Bio Trading Down 3.0%

Shares of Nuvation Bio stock opened at $4.22 on Monday. The firm has a market cap of $1.48 billion, a PE ratio of -10.55 and a beta of 1.73. The stock has a fifty day moving average price of $5.29 and a 200-day moving average price of $5.36. The company has a debt-to-equity ratio of 1.23, a current ratio of 7.45 and a quick ratio of 7.30. Nuvation Bio has a 1 year low of $3.97 and a 1 year high of $9.75.

Hedge Funds Weigh In On Nuvation Bio

A number of large investors have recently modified their holdings of NUVB. Sterling Capital Management LLC grew its stake in Nuvation Bio by 847.9% during the third quarter. Sterling Capital Management LLC now owns 8,389 shares of the company’s stock valued at $47,000 after acquiring an additional 7,504 shares in the last quarter. KBC Group NV purchased a new stake in Nuvation Bio in the 1st quarter worth approximately $37,000. GK Wealth Management LLC purchased a new stake in Nuvation Bio in the 3rd quarter worth approximately $52,000. Emergent Wealth Advisors LLC purchased a new stake in Nuvation Bio in the 3rd quarter worth approximately $67,000. Finally, Tortoise Investment Management LLC bought a new position in Nuvation Bio in the 2nd quarter valued at $78,000. 61.67% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Nuvation Bio news, insider Gary Hattersley sold 100,000 shares of Nuvation Bio stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $7.09, for a total transaction of $709,000.00. Following the completion of the transaction, the insider owned 100,000 shares of the company’s stock, valued at $709,000. The trade was a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 30.11% of the stock is owned by insiders.

About Nuvation Bio

Nuvation Bio is a biopharmaceutical company focused on developing and commercializing treatments for cancer. Founded in 2018 by physician and biotechnology executive David Hung, the company is headquartered in New York and is led by Hung as founder and chief executive officer. Its commercial product, Ibtrozi (taletrectinib), is an oral targeted therapy approved in the United States for adults with ROS1-positive non-small cell lung cancer. Nuvation Bio also develops investigational oncology medicines, including therapies targeting specific genetic changes and other features of cancer.